Table 2

Observed mean changes in PsA-modified vdH-S scores through week 100 in DISCOVER-2 patients evaluated in reading session 3*

Change in PsA-modified vdH-S score	Guselkumab Q4W				Guselkumab Q8W				Placebo (W0–24)→guselkumab Q4W (W24–100)
Change in PsA-modified vdH-S score	W0–24 N=221	W24–52 N=221	W52–100 N=211	W0–100 N=211	W0–24 N=228	W24–52 N=228	W52–100 N=216	W0–100 N=216	W0–24 N=215	W24–52 N=213	W52–100 N=202	W0–100 N=204
Total	0.5 (2.7)	0.6 (2.7)	0.8 (4.0)	1.7 (7.0)	0.7 (2.4)	0.3 (1.6)	0.5 (2.4)	1.5 (4.4)	1.1 (3.8)	0.3 (2.8)	0.1 (3.7)	1.5 (6.9)
Erosion	0.3 (1.9)	0.4 (1.8)	0.4 (2.9)	1.0 (4.7)	0.5 (2.0)	0.2 (1.2)	0.3 (1.8)	1.0 (3.4)	0.7 (2.2)	0.2 (1.8)	0.1 (2.0)	1.0 (4.0)
Joint space narrowing	0.2 (1.2)	0.2 (1.1)	0.3 (1.3)	0.7 (2.7)	0.2 (0.7)	0.1 (0.7)	0.2 (0.9)	0.5 (1.4)	0.4 (1.7)	0.1 (1.1)	0.04 (1.9)	0.5 (3.0)

Data presented as mean (SD).
*Reading session 3 included patients continuing study treatment at week 52 with images at weeks 0, 24, 52 and 100 (or at discontinuation after week 52).
PsA-modified vdH-S score, van der Heijde-Sharp score modified for psoriatic arthritis; Q4W, every 4 weeks; Q8W, every 8 weeks.